The JTC 2024 of TRANSCAN-3 call entitled"Translational research for new combination therapies against cancer: new opportunities for translational research" aims to develop preclinical patient models for combination therapies; translational research using tumor samples from retrospective and/or prospective patient cohorts.

Projects should be based on a solid and well-founded hypothesis and be relevant in terms of potential improvements in clinical practice.

Objective 1. development of new tumor models to test new drug combination therapies.

Objective 2. design and development of high-throughput drug combination screening platforms to test new combination therapies.

Objective 3: Use of combination strategies of immunotherapy and radiotherapy to overcome drug resistance.

Phase II clinical trials are excluded from the call.

Participating countries:

Austria, Belgium, Canada, France, Germany, Hungary, Italy, Latvia, Luxembourg, Norway, Poland, Romania, Slovakia, Spain, Taiwan, Turkey.

Timetable and funding conditions:

• July 05, 2024 - Project outline
• November 29 - full proposal
• Funding is available for collaborative projects with at least 3 to max. 6 partners (7 under certain conditions) from at least 3 participating countries
• 1 early researcher in the consortium
• Funding by the BMBF

Further information:

https://transcan.eu/funding/calls/joint-call-jtc-2024-.kl

Contact EPC

© TU Dresden

Project Manager

Name

Mr Dr. Stefan Schuldt

ERA-Nets, BMBF Complementary measures

Send email

Send encrypted email via the SecureMail portal (for TUD external users only).

Contact Information

Organization Name

European Project Center

European Project Center

Address work

Visiting address:

FAL Falkenbrunnen BT-A Würzburger Straße 35

01187 Dresden

Show map of this location.

work Tel.